Omega-3 (EPA and DHA): Inflammation, Brain and Heart Health
EPA and DHA do different jobs, dose matters more than most people assume, and the trial record is clearer than the public argument about it. A structured account.
The Short Answer
EPA and DHA are long-chain omega-3 fatty acids that incorporate into cell membranes, alter membrane fluidity and receptor behaviour, and serve as substrates for specialised pro-resolving mediators, the signalling molecules that actively end an inflammatory response rather than merely suppressing it. The trial record supports a dose-dependent pattern: intakes below about 1 gram per day of combined EPA and DHA produce small effects, while 2 to 4 grams per day produces reliable triglyceride reduction and measurable changes in inflammatory markers. DHA dominates in neural and retinal tissue, EPA dominates in the inflammatory resolution pathways, and the ratio between them should follow the objective.
EPA and DHA Are Not Interchangeable
Both are long-chain polyunsaturated omega-3 fatty acids, but their distribution and roles differ enough that handling them as one ingredient loses information.
DHA is a structural lipid. It makes up a large fraction of the fatty acids in retinal photoreceptor membranes and is heavily enriched in neuronal membranes, particularly at synapses. Its highly flexible structure changes membrane properties in ways that affect receptor conformation and neurotransmitter signalling. For anything concerning brain and eye structure, DHA is the relevant molecule.
EPA is more of a signalling substrate. It competes with arachidonic acid for the cyclooxygenase and lipoxygenase enzymes, shifting eicosanoid production toward less inflammatory species, and it is the precursor for the E-series resolvins. Cardiovascular and mood trials showing benefit have tended to use EPA-dominant formulations, and the trials using EPA-only preparations at high dose have produced the clearest cardiovascular outcome results.
Alpha-linolenic acid from flax, chia and walnuts is an omega-3 but not a substitute. Conversion to EPA is inefficient, typically under ten percent, and conversion to DHA is lower still, often under one percent in men. Someone relying on flaxseed for DHA is not achieving it.
The Trial Record, Read Carefully
Omega-3 research is often summarised as contradictory. Read by dose and by formulation it is considerably more coherent.
Low-dose trials
Large cardiovascular trials using around 1 gram per day of mixed EPA and DHA have generally been null for major endpoints. This includes several well-conducted studies in high-cardiovascular-burden populations. A reasonable interpretation is that 1 gram per day is a nutritional intake rather than a pharmacological one.
High-dose trials
A large trial using 4 grams per day of purified EPA ethyl ester in people with elevated triglycerides on statin therapy reported a substantial reduction in major cardiovascular events. A comparable trial using a mixed EPA and DHA preparation at a similar dose did not show the same benefit, which has generated genuine scientific debate about whether the difference is due to EPA specifically, to the comparator oil used, or to other factors. The debate is unresolved and worth acknowledging rather than resolving by preference.
Triglycerides
This is the most consistent finding in the entire literature. Combined EPA and DHA at 2 to 4 grams per day reduces fasting triglycerides substantially, with the effect proportional to both dose and starting concentration. It is dependable enough that prescription omega-3 preparations exist for this purpose.
Inflammatory markers
Meta-analyses report reductions in C-reactive protein, interleukin-6 and tumour necrosis factor alpha, generally at doses above 2 grams per day and over eight weeks or more. Effect sizes are modest and most reliable in populations with elevated baseline inflammation.
Cognition and mood
Results in cognitively healthy adults are mixed to null over typical trial durations. Mood trials show more promise, with meta-analyses favouring EPA-dominant formulations at 1 to 2 grams of EPA per day as an adjunct rather than a stand-alone approach. Observational data consistently associate higher DHA status with slower cognitive decline, which is suggestive but not causal.
Dose and Ratio, by Objective
- General nutritional adequacy: 500 mg to 1 g per day of combined EPA and DHA, which approximates two portions of oily fish per week.
- Triglyceride reduction: 2 to 4 g per day combined. This is the dose range with dependable effect and typically requires a concentrated preparation rather than standard fish oil.
- Inflammatory objectives: above 2 g per day, EPA-weighted, sustained for at least eight to twelve weeks.
- Mood support as an adjunct: 1 to 2 g per day of EPA specifically, with EPA exceeding DHA in the formulation.
- Neural and retinal structure: DHA-weighted, at least 500 mg to 1 g of DHA per day.
Read the label arithmetic, not the front of the bottle. A "1,000 mg fish oil" capsule commonly contains 180 mg EPA and 120 mg DHA, meaning 300 mg of what matters. Reaching 2 grams of combined EPA and DHA from that product takes roughly seven capsules a day, which is why concentrated preparations exist and why so many people believe they are taking a therapeutic dose when they are taking a nutritional one.
Form, Oxidation and Product Quality
Omega-3s exist in supplements as triglycerides, re-esterified triglycerides, ethyl esters, phospholipids in krill oil, or free fatty acids. Absorption differences are real but generally modest and largely resolved by taking the product with a fat-containing meal, which improves absorption of ethyl esters substantially.
Oxidation is the more important quality issue and receives far less attention. Long-chain polyunsaturated fats are highly susceptible to peroxidation, and independent testing has repeatedly found products on the market exceeding recommended oxidation limits. An oxidised fish oil is not merely inert; peroxidation products are themselves undesirable.
Signals worth acting on: a stated peroxide value and total oxidation number from third-party testing, an intact antioxidant system in the formulation, cool storage, and a genuine expiry date. The old advice about breaking a capsule and smelling it is crude but not useless. Rancidity is detectable.
Krill oil delivers omega-3s in phospholipid form with astaxanthin included and shows good bioavailability per gram, but delivers far less EPA and DHA per capsule, which makes reaching a pharmacological dose expensive. Algal oil is the practical route to DHA for anyone avoiding fish and is the original source of the fatty acid in the marine food chain.
Measuring Omega-3 Status
Unlike most supplements, omega-3 status is directly measurable. The omega-3 index reports EPA plus DHA as a percentage of total fatty acids in red blood cell membranes, which reflects intake over the preceding months rather than the last meal.
Population data associate an index below 4 percent with less favourable cardiovascular outcomes and an index above 8 percent with more favourable ones, and the 8 to 12 percent range is the commonly cited target. Most people in Western countries without supplementation or high fish intake sit between 4 and 6 percent.
This measurability changes the nature of the decision. Rather than guessing at dose, a person can measure, adjust and re-measure after three to four months, which is the time required for membrane composition to reflect a new intake. It is one of the few supplements where titrating to a target is straightforward.
Safety, Bleeding and Practical Cautions
Omega-3s are well tolerated. The common effects are gastrointestinal: reflux, fishy aftertaste, loose stools at higher doses. Taking the dose with food, splitting it, or freezing capsules reduces most of this.
The bleeding question is frequently overstated and should not be dismissed either. High-dose omega-3s have a mild antiplatelet effect. Large trials at 4 grams per day did not show clinically important bleeding increases in general populations, but anyone on anticoagulant or antiplatelet therapy, and anyone approaching surgery, should be having that conversation with their clinician rather than making an assumption in either direction.
Two further points. High-dose EPA-only preparations were associated with a higher incidence of atrial fibrillation in some large trials, which is a real signal that belongs in the decision for anyone with a rhythm history. And in people with very high triglycerides, DHA-containing preparations can raise LDL cholesterol somewhat, which is worth knowing when interpreting a follow-up lipid panel.
When to Reassess
Omega-3 is a slow compound with a fast-feeling reputation. Membrane incorporation takes months, and the omega-3 index does not stabilise on a new intake for three to four months. Judging it in three weeks measures nothing.
The natural reassessment cycle follows the measurement: measure the index, adjust dose, re-measure after four months, then annually once at target. If the objective is triglyceride reduction, the lipid panel provides the endpoint on a similar timescale. If the objective is inflammatory, an inflammatory marker panel at twelve weeks is a fair test.
Context changes that should trigger a review: a substantial change in fish intake, starting anticoagulant therapy, a planned procedure, a new rhythm concern, or a change in the objective itself from cardiovascular to cognitive, which changes the EPA to DHA ratio that makes sense.
The AEONNN Perspective
Omega-3 is one of the few compounds where AEONNN can close the loop from recommendation to measurement to adjustment, because the omega-3 index is a direct, stable and inexpensive readout of the intervention. For a member in Synched Mode with a connected index result, Stack Builder is not estimating a dose; it is titrating one.
The compound maps across Inflammation and Immune Defense, Cognition and Neuroprotection, and Metabolic and Cardiovascular Health, and the EPA to DHA ratio that makes sense differs across those three. This is precisely why the Pillar Matrix matters: the same ingredient serves different Pillars at different ratios, and a single-number recommendation would be wrong for at least two of them.
The Quality and Formulation layer carries real weight here because oxidation is common, invisible on a label and consequential. And the Safety layer holds two specific items that override preference: the antiplatelet consideration and the atrial fibrillation signal at high-dose EPA. Both are checked before dose reasoning begins.
Pillar Matrix mapping
Inflammation and Immune Defense, Cognition and Neuroprotection, Metabolic and Cardiovascular Health
Database Matrix layers
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
- Pharmacokinetics Layer (HMDB, PubChem)
- Quality / Formulation Layer (ConsumerLab, Labdoor)
- Population Layer (UK Biobank, NHANES)
Frequently Asked
How much omega-3 should be taken per day?
For general adequacy, 500 mg to 1 g per day of combined EPA and DHA. For triglyceride reduction or inflammatory objectives, 2 to 4 g per day, which usually requires a concentrated preparation. Check the EPA and DHA amounts rather than the total fish oil weight.
What is the difference between EPA and DHA?
DHA is primarily structural and concentrated in neural and retinal membranes. EPA is primarily a signalling substrate that competes with arachidonic acid and feeds the resolvin pathways. Neural objectives favour DHA; inflammatory and mood objectives favour EPA.
Why were some large fish oil trials negative?
Most null trials used around 1 gram per day, which is a nutritional rather than pharmacological intake. The trial reporting substantial cardiovascular benefit used 4 grams per day of purified EPA. Dose and formulation explain much of the apparent contradiction.
What is a good omega-3 index?
The commonly cited target is 8 to 12 percent of red blood cell fatty acids as EPA plus DHA. Most people without supplementation or high fish intake sit between 4 and 6 percent. Membrane composition takes three to four months to reflect a change in intake.
Is krill oil better than fish oil?
Krill oil delivers omega-3s in phospholipid form with good bioavailability per gram and includes astaxanthin, but contains far less EPA and DHA per capsule. Reaching a pharmacological dose with krill oil is expensive.
Can flaxseed replace fish oil?
No. Alpha-linolenic acid from flax converts to EPA at under ten percent efficiency and to DHA at often under one percent. Algal oil is the appropriate plant-based route to DHA.
Does fish oil thin the blood?
It has a mild antiplatelet effect. Large trials at 4 grams per day did not show clinically important bleeding increases in general populations, but anyone on anticoagulant or antiplatelet therapy or approaching surgery should discuss it with their clinician.
How can I tell if my fish oil has gone rancid?
Third-party peroxide value and total oxidation testing is the reliable answer. Practically, a strongly fishy or acrid smell when a capsule is opened indicates oxidation. Store cool and respect the expiry date.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.